美国的低氧细胞增敏剂项目。
The hypoxic cell sensitizer programme in the United States.
作者信息
Phillips T L, Wasserman T H, Gomer C J, Lawrence G A, Levine M L, Sadee W, Penta J S, Rubin D J
出版信息
Br J Cancer Suppl. 1978 Jun;3:276-80.
Abstract
The initial results of a Phase I evaluation of misonidazole in the U.S.A. are described, as well as the U.S. National Cancer Institute programme for radiosensitizer development. A total of 12 patients have been given 1--6 doses of 1--2 g/m2. Serum levels ranged from 25--87 microgram/ml at 4--6 h. One patient has developed mild peripheral neuropathy. Urinary excretion was chiefly of a demethylated metabolite as measured by HPLC assay.
摘要
本文描述了美国米索硝唑一期评估的初步结果，以及美国国立癌症研究所的放射增敏剂研发计划。共有12名患者接受了1-6剂、每平方米1-2克的治疗。4-6小时时血清水平在25-87微克/毫升之间。一名患者出现了轻度周围神经病变。通过高效液相色谱法测定，尿液排泄主要是一种去甲基代谢物。
相似文献
1
The hypoxic cell sensitizer programme in the United States.美国的低氧细胞增敏剂项目。
Br J Cancer Suppl. 1978 Jun;3:276-80.
2
Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.乏氧细胞放射增敏剂米索硝唑I期研究的进一步临床经验
Br J Cancer Suppl. 1978 Jun;3:281-5.
3
[Clinical trials of hypoxic cell sensitizer misonidazole].[乏氧细胞增敏剂米索硝唑的临床试验]
Gan No Rinsho. 1983 May;29(6):718-25.
4
Some aspects of the metabolism of misonidazole.米索硝唑代谢的某些方面。
Br J Cancer Suppl. 1978 Jun;3:264-7.
5
Clinical trials of misonidazole in the United States.
Cancer Clin Trials. 1981;4(1):7-16.
6
Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Cancer Res. 1987 Jan 1;47(1):319-22.
7
Misonidazole in the preoperative and radical radiotherapy of bladder cancer.米索硝唑在膀胱癌术前及根治性放疗中的应用
Cancer Clin Trials. 1980 Fall;3(3):275-80.
8
Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.缺氧细胞放射增敏剂SR - 2508的I期试验初步报告。
Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1749-53. doi: 10.1016/0360-3016(84)90542-x.
9
Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.2-硝基咪唑衍生物低氧细胞放射增敏剂RO-07-0582的临床I期研究
Radiology. 1977 Mar;122(3):801-4. doi: 10.1148/122.3.801.
10
Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole.乏氧细胞放射增敏剂米索硝唑的药代动力学和代谢研究。
Xenobiotica. 1978 Feb;8(2):97-105. doi: 10.3109/00498257809060388.
引用本文的文献
1
Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks.使用γH2AX作为DNA双链断裂的分子标志物评估辐射修饰化合物的疗效。
Genome Integr. 2011 Jan 25;2(1):3. doi: 10.1186/2041-9414-2-3.
2
Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.通过全身放射自显影研究放射增敏剂2-[¹⁴C]米索硝唑（Ro 07-0582）在小鼠和大鼠体内的分布及肿瘤渗透特性。
Cancer Chemother Pharmacol. 1986;17(2):121-6. doi: 10.1007/BF00306739.
3
The demonstration of in vivo misonidazole tumour toxicity using post radiation hypoxia.利用放疗后缺氧情况对米索硝唑的体内肿瘤毒性进行的论证。
Br J Cancer Suppl. 1978 Jun;3:228-31.
本文引用的文献
1
Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results.放射增敏剂Ro-07-0582在人体中的血清浓度测量：一些初步结果。
Br J Cancer. 1975 Jun;31(6):679-83. doi: 10.1038/bjc.1975.115.
2
Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.放射增敏剂Ro 07-0582的临床试验：多次给药的经验
Br J Cancer. 1977 May;35(5):567-79. doi: 10.1038/bjc.1977.90.
3
Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.放射增敏剂Ro-07-0582的临床试验。I. 剂量耐受性、血清和肿瘤浓度。
Clin Radiol. 1976 Apr;27(2):151-7. doi: 10.1016/s0009-9260(76)80137-7.
Zotero 插件